Researchers have identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigments (RP).
Welcome to ModernMedicine
The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED) certification from the U.S. Green Building Council.
William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.
Implantable contact lens and preloaded IOL manufacturing will move to California in a consolidation project now under way at STAAR Surgical.
Glaucoma may be a significant predictor of depression, according to research published in the American Journal of Ophthalmology.
The FDA approved OptiMedica's Catalys Precision for creating single-plane and multi-plane arc incisions in the cornea during cataract surgery.
A trifocal diffractive intraocular lens (FineVision IOL, PhysIOL) reduces spectacle dependence after cataract surgery and provides patient satisfaction.
Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost punctum plug for treating ocular hypertension and glaucoma.
Gevokizumab, an IL-1 beta-modulating antibody from XOMA Corp., has received FDA orphan drug designation for the treatment of several types of non-infectious uveitis.
Allergan Inc. and Molecular Partners AG have entered into two agreements to discover, develop, and commercialize proprietary therapeutic designed ankyrin repeat protein (DARPin) products for the treatment of opthalmic diseases.